| ORIC PHARMACEUTICALS |
| USA |
| Gesundheit |
| US68622P1093 / A2P208 |
| 4TZ (Frankfurt) / ORIC (NASDAQ) |
| FRA:4TZ, ETR:4TZ, 4TZ:GR, NASDAQ:ORIC |
| - |
| https://oricpharma.com/ |
|
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key ..
>Volltext.. |
| 1153.95 Mio. EUR |
| 921.48 Mio. EUR |
| - |
| -137.82 Mio. EUR |
| -124.8 Mio. EUR |
| -1.2 EUR |
| 2.96 Mio. EUR |
| 33.33 Mio. EUR |
| -101.7 Mio. EUR |
| 12.76 |
| - |
| -2.26% |
| - |
| - |
| - |
| ORIC PHARMACEUTICALS, ORIC PHARMA, ORIC PHARMACEUTICAL |
| 03.10.26 |